|
WO2006004917A2
|
|
Method of treating breast cancer using a combination of 1alpha, 24-dihydroxyvitamin d2 and a further chemotherapeutic agent
|
|
US2005239756A1
|
|
Methods of treating various vitamin D metabolism conditions with 1alpha-hydroxyvitamin D2
|
|
US2006003950A1
|
|
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
|
|
US2004058895A1
|
|
Multi-use vessels for vitamin D formulations
|
|
US2004009958A1
|
|
Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
|
|
US2004043971A1
|
|
Method of treating and preventing hyperparathyroidism with active vitamin D analogs
|
|
US2003129194A1
|
|
Targeted therapeutic delivery of vitamin D compounds
|
|
US2004053895A1
|
|
Multi-use vessels for vitamin D formulations
|
|
US2002183288A1
|
|
Method for treating and preventing hyperparathyroidism
|
|
US2002128240A1
|
|
Treatment of hyperproliferative diseases using active vitamin D analogues
|
|
EP1301479A2
|
|
STABILIZED 1$g(a)-HYDROXY VITAMIN D
|
|
US2002025950A1
|
|
Method of treating hyperproliferative diseases using active vitamin D analogues
|
|
US2002010165A1
|
|
Method of treating malignancy associated hypercalcemia using active vitamin D analogues
|
|
US2002019375A1
|
|
Method of inhibiting angiogenesis using active vitamin D analogues
|
|
US2002032179A1
|
|
Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
|
|
US6376479B1
|
|
Method for treating and preventing hyperparathyroidism
|
|
US6359012B1
|
|
Method for making 24(S)-hydroxyvitamin D2
|
|
CN1303369A
|
|
Method for making hydroxy-25-ene-vitamin D compounds
|
|
BR9910692A
|
|
Process for the preparation of hydroxy-25-ene-vitamin d compounds
|
|
US6251883B1
|
|
Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
|
